Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2012 May;27(5):476-83.
doi: 10.3346/jkms.2012.27.5.476. Epub 2012 Apr 25.

Comparison of ertapenem and ceftriaxone therapy for acute pyelonephritis and other complicated urinary tract infections in Korean adults: a randomized, double-blind, multicenter trial

Dae Won Park  1 , Kyong Ran Peck, Moon Hyun Chung, Jin Seo Lee, Yoon Soo Park, Hyo Youl Kim, Mi Suk Lee, Jung Yeon Kim, Joon Sup Yeom, Min Ja Kim
Affiliations
Randomized Controlled Trial

Comparison of ertapenem and ceftriaxone therapy for acute pyelonephritis and other complicated urinary tract infections in Korean adults: a randomized, double-blind, multicenter trial

Dae Won Park et al. J Korean Med Sci. 2012 May.

Abstract

The efficacy and safety of ertapenem, 1 g once daily, were compared with that of ceftriaxone, 2 g once daily, for the treatment of adults with acute pyelonephritis (APN) and complicated urinary tract infections (cUTIs) in a prospective, multicenter, double-blinded, randomized study. After ≥ 3 days of parenteral study therapy, patients could be switched to an oral agent. Of 271 patients who were initially stratified by APN (n = 210) or other cUTIs (n = 61), 66 (48.9%) in the ertapenem group and 71 (52.2%) in the ceftriaxone group were microbiologically evaluable. The mean duration of parenteral and total therapy, respectively, was 5.6 and 13.8 days for ertapenem and 5.8 and 13.8 days for ceftriaxone. The most common pathogen was Escherichia coli. At the primary efficacy endpoint 5-9 days after treatment, 58 (87.9%) patients in the ertapenem group and 63 (88.7%) in the ceftriaxone had a favorable microbiological response. When compared by stratum and severity, the outcomes in the two groups were equivalent. The frequency and severity of drug-related adverse events were generally similar in both treatment groups. The results indicate that ertapenem is highly effective and safe for the treatment of APN and cUTIs.

Keywords: Ceftriaxone; Ertapenem; Pyelonephritis; Urinary Tract Infections.

PubMed Disclaimer

Conflict of interest statement

Min Ja Kim and Kyong Ran Peck report receiving consulting fees from MSD Korea Ltd. but there was no influence on conducting study, interpretation of results, and writing this article. All other authors report no competing interests.

Figures

Fig. 1
Fig. 1
Profile of patient enrollment.
See this image and copyright information in PMC

References

    1. Lichtenberger P, Hooton TM. Complicated urinary tract infections. Curr Infect Dis Rep. 2008;10:499–504. - PubMed
    1. Ronald AR, Nicolle LE, Stamm E, Krieger J, Warren J, Schaeffer A, Naber KG, Hooton TM, Johnson J, Chambers S, et al. Urinary tract infection in adults: research priorities and strategies. Int J Antimicrob Agents. 2001;17:343–348. - PubMed
    1. Ki M, Park T, Choi B, Foxman B. The epidemiology of acute pyelonephritis in South Korea, 1997-1999. Am J Epidemiol. 2004;160:985–993. - PubMed
    1. Nicolle L AMMI Canada Guidelines Committee. Complicated urinary tract infection in adults. Can J Infect Dis Med Microbiol. 2005;16:349–360. - PMC - PubMed
    1. Warren JW, Abrutyn E, Hebel JR, Johnson JR, Schaeffer AJ, Stamm WE. Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Infectious Diseases Society of America (IDSA) Clin Infect Dis. 1999;29:745–758. - PubMed

Publication types